Radiopharmaceutical Proposed Reg May Reduce Submission Costs
Executive Summary
FDA's radiopharmaceutical proposed rule may reduce the cost of drug submissions, CDER Associate Director for Policy Jane Axelrad told a Food and Drug Law Institute conference during her analysis of FDA's "Regulations for In Vivo Radiopharmaceuticals Used for Diagnosis and Monitoring" on May 21.